Tina S Skinner-Adams

List of Publications by Year
in descending order

71 papers	3,074 citations	147801 31 h-index	168389 53 g-index
73 all docs	73 docs citations	73 times ranked	3776 citing authors

#	Article	IF	Citations
1	QSAR Classification Models for Prediction of Hydroxamate Histone Deacetylase Inhibitor Activity against Malaria Parasites. ACS Infectious Diseases, 2022, 8, 106-117.	3.8	8
2	Antiplasmodial activity of the natural product compounds alstonine and himbeline. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 16, 17-22.	3.4	11
3	Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 118-127.	3.4	3
4	Anti-Giardia Drug Discovery: Current Status and Gut Feelings. Journal of Medicinal Chemistry, 2020, 63, 13330-13354.	6.4	34
5	The Key Glycolytic Enzyme Phosphofructokinase Is Involved in Resistance to Antiplasmodial Glycosides. MBio, 2020, 11, .	4.1	5
6	An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 14, 249-256.	3.4	3
7	An image-based Pathogen Box screen identifies new compounds with anti-Giardia activity and highlights the importance of assay choice in phenotypic drug discovery. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 12, 60-67.	3.4	3
8	Drug resistance in Giardia: Mechanisms and alternative treatments for Giardiasis. Advances in Parasitology, 2020, 107, 201-282.	3.2	53
9	A Sesquiterpene Isonitrile with a New Tricyclic Skeleton from the Indo-Pacific Nudibranch Phyllidiella pustulosa: Spectroscopic and Computational Studies. Australian Journal of Chemistry, 2020, 73, 129.	0.9	9
10	Structureâ€“Activity and Structureâ€“Toxicity Relationships of Peptoidâ€Based Histone Deacetylase Inhibitors with Dualâ€Stage Antiplasmodial Activity. ChemMedChem, 2019, 14, 912-926.	3.2	24
11	Proteomic analysis of Plasmodium falciparum histone deacetylase 1 complex proteins. Experimental Parasitology, 2019, 198, 7-16.	1.2	8
12	Identification of novel quinazoline derivatives as potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2019, 161, 277-291.	5.5	44
13	Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry. ACS Infectious Diseases, 2018, 4, 431-444.	3.8	50
14	Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 189-193.	3.4	20
15	Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 42-50.	3.4	82
16	A novel inÂvitro image-based assay identifies new drug leads for giardiasis. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 83-89.	3.4	20
17	Synthesis, biological characterisation and structure activity relationships of aromatic bisamidines active against Plasmodium falciparum. European Journal of Medicinal Chemistry, 2017, 127, 22-40.	5.5	13
18	Catalyst-Controlled Stereoselective Synthesis Secures the Structure of the Antimalarial Isocyanoterpene Pustulosaisonitrile-1. Journal of Organic Chemistry, 2017, 82, 13313-13323.	3.2	25

#	Article	IF	Citations
19	A Plasmodium falciparum S33 proline aminopeptidase is associated with changes in erythrocyte deformability. Experimental Parasitology, 2016, 169, 13-21.	1.2	15
20	Adaptation of the [³ H]Hypoxanthine Uptake Assay for In Vitro -Cultured Plasmodium knowlesi Malaria Parasites. Antimicrobial Agents and Chemotherapy, 2016, 60, 4361-4363.	3.2	13
21	Defining the targets of antiparasitic compounds. Drug Discovery Today, 2016, 21, 725-739.	6.4	25
22	Synthesis and Antiplasmodial Evaluation of Analogues Based on the Tricyclic Core of Thiaplakortones Aâ€“D. Marine Drugs, 2015, 13, 5784-5795.	4.6	5
23	Antimalarial Isocyano and Isothiocyanato Sesquiterpenes with Tri- and Bicyclic Skeletons from the Nudibranch Phyllidia ocellata. Journal of Natural Products, 2015, 78, 1422-1427.	3.0	26
24	Synthesis and antimalarial evaluation of amide and urea derivatives based on the thiaplakortone A natural product scaffold. Organic and Biomolecular Chemistry, 2015, 13, 1558-1570.	2.8	25
25	Synthesis, Antimalarial Properties, and SAR Studies of Alkoxyureaâ€Based HDAC Inhibitors. ChemMedChem, 2014, 9, 665-670.	3.2	26
26	Drug repurposing and human parasitic protozoan diseases. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 95-111.	3.4	286
27	Lysine Acetylation in Sexual Stage Malaria Parasites Is a Target for Antimalarial Small Molecules. Antimicrobial Agents and Chemotherapy, 2014, 58, 3666-3678.	3.2	62
28	Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening. Journal of Biomolecular Screening, 2014, 19, 1107-1115.	2.6	15
29	Total Synthesis of Thiaplakortone A: Derivatives as Metabolically Stable Leads for the Treatment of Malaria. ACS Medicinal Chemistry Letters, 2014, 5, 178-182.	2.8	26
30	Mollemycin A: An Antimalarial and Antibacterial Glyco-hexadepsipeptide-polyketide from an Australian Marine-Derived Streptomyces sp. (CMB-M0244). Organic Letters, 2014, 16, 1716-1719.	4.6	41
31	Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6114-6117.	2.2	30
32	Plasmodium Gametocyte Inhibition Identified from a Natural-Product-Based Fragment Library. ACS Chemical Biology, 2013, 8, 2654-2659.	3.4	39
33	Plasmodium falciparumgametocytes: with a view to a kill. Parasitology, 2013, 140, 1718-1734.	1.5	25
34	HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 995-1000.	3.2	17
35	The Aminopeptidase Inhibitor CHR-2863 Is an Orally Bioavailable Inhibitor of Murine Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3244-3249.	3.2	35
36	Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939. Antimicrobial Agents and Chemotherapy, 2012, 56, 3849-3856.	3.2	74

#	Article	IF	Citations
37	Saquinavir Inhibits the Malaria Parasite's Chloroquine Resistance Transporter. Antimicrobial Agents and Chemotherapy, 2012, 56, 2283-2289.	3.2	26
38	Psammaplysin Derivatives from the Balinese Marine Sponge Aplysinella strongylata. Journal of Natural Products, 2012, 75, 2132-2143.	3.0	40
39	Fingerprinting the Substrate Specificity of M1 and M17 Aminopeptidases of Human Malaria, Plasmodium falciparum. PLoS ONE, 2012, 7, e31938.	2.5	64
40	The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment. PLoS ONE, 2012, 7, e34399.	2.5	13
41	Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends in Biochemical Sciences, 2010, 35, 53-61.	7.5	108
42	Antimalarial Asexual Stage-Specific and Gametocytocidal Activities of HIV Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2010, 54, 1334-1337.	3.2	33
43	Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2449-2454.	7.1	80
44	Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2537-2542.	7.1	133
45	Inhibition of Hypoxanthine-Guanine Phosphoribosyltransferase by Acyclic Nucleoside Phosphonates: A New Class of Antimalarial Therapeutics. Journal of Medicinal Chemistry, 2009, 52, 4391-4399.	6.4	107
46	Plasmodium falciparum: new molecular targets with potential for antimalarial drug development. Expert Review of Anti-Infective Therapy, 2009, 7, 1087-1098.	4.4	32
47	HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends in Parasitology, 2008, 24, 264-271.	3.3	69
48	Potent Antimalarial Activity of Histone Deacetylase Inhibitor Analogues. Antimicrobial Agents and Chemotherapy, 2008, 52, 1454-1461.	3.2	112
49	Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrobial Agents and Chemotherapy, 2008, 52, 2435-2441.	3.2	34
50	The M18 Aspartyl Aminopeptidase of the Human Malaria Parasite Plasmodium falciparum. Journal of Biological Chemistry, 2007, 282, 30817-30826.	3.4	48
51	Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 759-762.	3.2	52
52	Antimalarial activity of sera from subjects taking HIV protease inhibitors. Aids, 2007, 21, 763-765.	2.2	28
53	Characterization of the Plasmodium falciparum M17 Leucyl Aminopeptidase. Journal of Biological Chemistry, 2007, 282, 2069-2080.	3.4	111
54	Identification of Phosphinate Dipeptide Analog Inhibitors Directed against the Plasmodiumfalciparum M17 Leucine Aminopeptidase as Lead Antimalarial Compounds. Journal of Medicinal Chemistry, 2007, 50, 6024-6031.	6.4	84

#	Article	IF	Citations
55	The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. International Journal of Antimicrobial Agents, 2007, 29, 98-102.	2.5	39
56	Overexpression of Leucyl Aminopeptidase in Plasmodium falciparum Parasites. Journal of Biological Chemistry, 2006, 281, 1741-1745.	3.4	55
57	Lead Compounds for Antimalarial Chemotherapy:Â Purine Base Analogs Discriminate between Human andP.Falciparum6-Oxopurine Phosphoribosyltransferases. Journal of Medicinal Chemistry, 2006, 49, 7479-7486.	6.4	55
58	Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria. Antimicrobial Agents and Chemotherapy, 2006, 50, 639-648.	3.2	130
59	Implication of a Plasmodium falciparum gene in the switch between asexual reproduction and gametocytogenesis. Molecular and Biochemical Parasitology, 2005, 140, 153-160.	1.1	36
60	A novel Plasmodium falciparum ring stage protein, REX, is located in Maurerâ€™s clefts. Molecular and Biochemical Parasitology, 2004, 136, 181-189.	1.1	81
61	Characterization of the effect of retinol on Plasmodium falciparum in vitro. Experimental Parasitology, 2004, 107, 136-144.	1.2	12
62	CLAGï¿½9 is located in the rhoptries of Plasmodium falciparum. Parasitology Research, 2004, 93, 64-67.	1.6	22
63	GATEWAYâ„¢ vectors for Plasmodium falciparum transfection. Trends in Parasitology, 2003, 19, 17-18.	3.3	11
64	Malaria transfection and transfection vectors. Trends in Parasitology, 2003, 19, 381-383.	3.3	26
65	In vitro antimalarial activity of retinoids and the influence of selective retinoic acid receptor antagonists. Acta Tropica, 2003, 87, 345-353.	2.0	16
66	Plasmodium falciparum: Isolate-Specific Radiosensitivity. Experimental Parasitology, 2001, 99, 108-110.	1.2	2
67	Antiplasmodial and Antioxidant Isofuranonaphthoquinones from the Roots of Bulbine capitata. Planta Medica, 2001, 67, 340-344.	1.3	30
68	In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone. Acta Tropica, 2000, 74, 39-42.	2.0	20
69	Synergistic In Vitro Antimalarial Activity of Omeprazole and Quinine. Antimicrobial Agents and Chemotherapy, 1999, 43, 1304-1306.	3.2	27
70	In vitro growth inhibition of Plasmodium falciparum by retinol at concentrations present in normal human serum. Acta Tropica, 1998, 69, 111-119.	2.0	28
71	In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. International Journal for Parasitology, 1996, 26, 519-525.	3.1	110